The short answer
Body composition is inferred rather than observed. Dual-energy X-ray absorptiometry and bioimpedance rest on different assumptions and produce different answers, and they diverge most during active weight loss when hydration is shifting.
Key facts
- DXA principle
- Differential X-ray attenuation
- Bioimpedance principle
- Electrical resistance of tissue
- Bioimpedance depends on
- Hydration status
- Worst agreement
- During active weight change
- Comparison study
- Vermeiren 2021 (PMID 32917962)
- Neither is
- A direct measurement of muscle
Why nothing here is measured directly
Determining tissue composition directly would require dissection. Every practical method infers composition from a physical property that correlates with it, using assumptions about how tissues behave. Those assumptions are reasonable in stable individuals and get less reliable exactly when body composition is changing, which is when these measurements are wanted.
How DXA works and where it strains
Two X-ray energies pass through the body and are attenuated differently by bone, fat and lean tissue, and composition is calculated from the differential. It is the most widely accepted method and it still assumes a fixed hydration fraction for lean tissue. When hydration changes, that assumption introduces error into the lean mass figure.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
How bioimpedance works and why it is more fragile
A small current is passed through the body and resistance measured. Lean tissue conducts well because it holds water and electrolytes; fat conducts poorly. The method is therefore measuring body water and inferring lean mass from it. Anything altering hydration, a meal, exercise, time of day, a diuretic,moves the reading without any tissue changing.
What the comparison studies show
Vermeiren and colleagues compared bioimpedance spectroscopy against DXA for assessing body composition changes during weight loss in the European Journal of Clinical Nutrition in 2021. Studies of this kind consistently find the methods agree less well for change than for a single snapshot, which matters because change is what weight-loss trials report.
Why this undermines cross-trial comparison
A trial using DXA and a trial using bioimpedance are not producing interchangeable numbers, and a difference between them may reflect instrumentation rather than biology. When lean mass percentages from different trials are placed side by side, the method used is as relevant as the compound, and is usually not mentioned.
What would actually settle a functional question
Function. Grip strength, gait speed, stair climbing and similar measures test whether anything consequential changed, and they do not depend on an inference about tissue compartments. A trial reporting preserved lean mass without functional measures has reported a proxy.
Quick reference
| DXA | Bioimpedance | |
|---|---|---|
| Measures | X-ray attenuation | Electrical resistance |
| Infers lean mass from | Tissue density | Body water |
| Hydration sensitivity | Moderate | High |
| Availability | Clinical/research | Widely available |
Frequently asked questions
Is DXA a direct measurement of muscle?
No. It infers composition from differential X-ray attenuation and assumes a fixed hydration fraction for lean tissue.
Why is bioimpedance more variable?
It measures body water and infers lean mass from it, so meals, exercise, time of day and hydration all move the reading.
Can I compare lean mass figures across trials?
Cautiously at best. Different methods do not produce interchangeable numbers, and they agree least on change.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedVermeiren E et al., Comparison of bioimpedance spectroscopy and dual energy X-ray absorptiometry for assessing body composition changes during weight loss. Eur J Clin Nutr 2021 (PMID 32917962)pubmed.ncbi.nlm.nih.gov
- PubMedDubin RL et al., GLP-1 agents and weight loss composition. Diabetes Obes Metab 2024 (PMID 39344838)pubmed.ncbi.nlm.nih.gov
- PubMedStefanakis K et al. Metabolism 2024 (PMID 39481534)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Blocking the Brake on Muscle GrowthMyostatin restrains muscle growth through activin type II receptors. Blocking them preserves muscle - and a 2024 paper reports it enhances fat loss too.
- Taldefgrobep Alfa: A Second Route Into the Same PathwayA myostatin-directed agent now in a Phase 2 obesity trial. Why more than one compound is targeting the same pathway from different angles.
- The Endpoint Changes When the Patient Is Still GrowingAdult trials report percentage weight loss. Adolescent trials report percent change in BMI - because a growing child gaining height is not failing.
- STEP TEENS and What It Reported201 adolescents, 68 weeks, −16.1% BMI against +0.6% on placebo. The full result including the safety findings that get left out.
- What Is Actually Registered, and at What PhaseA Phase 3 in 160 adolescents aged 12-17, and a Phase 1 safety study in 28 children aged 6-11. The distinction matters for what results will mean.